Table I.
Characteristics of MS patients and HC for flow cytometry
| Number | Agea | Gender % F | EDSSb | Previous treatmentc | % DN B cellsd | |
|---|---|---|---|---|---|---|
| HC | 48 | 45.7±15.6 | 68.8 % | N.A. | N.A. | 4.4±2.0 |
| MS total | 96 | 44.1±13.4 | 72.9 % | 3.4±2.2 | UT: 84, IFN: 9, GA: 2, TF: 1 | 6.1±3.8 |
| RRMS | 63 | 38.8±11.6 | 69.8 % | 2.3±1.4 | UT: 54, IFN: 6, GA: 2, TF: 1 | 6.1±3.5 |
| PPMS | 13 | 52.1±8.7 | 61.5 % | 5.4±2.0 | UT: 13 | 6.0±4.0 |
| SPMS | 20 | 55.9±11 | 90.0 % | 5.8±1.6 | UT: 17, IFN: 3 | 5.9±4.5 |
a
in years, presented as mean ± SD
b
presented as mean ± SD
c
all previous treatments are shown for RRMS and PPMS patients, previous treatments ≤ 6 months prior to sampling are shown for SPMS patients
d
within CD19+ B cells, presented as mean ± SD; Abbreviations: HC, healthy controls; MS, multiple sclerosis; RR, relapsing-remitting; PP, primary progressive; SP, secondary progressive; F, female; EDSS, expanded disability status scale; N.A., not applicable; UT, untreated; IFN, interferon-β; GA, glatiramer acetate, TF: teriflunomide